| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
1 Department of Molecular Medicine, Osaka University Graduate School of Medicine, Yamada-oka 2-2, Suita, 565-0871 Osaka, Japan
2 Department of Pathology, Osaka University Graduate School of Medicine, Yamada-oka 2-2, Suita, 565-0871 Osaka, Japan
3 Department of Surgery and Clinical Oncology, Osaka University Graduate School of Medicine, Yamada-oka 2-2, Suita, 565-0871 Osaka, Japan
Correspondence: Address correspondence and reprint requests to: Hideji Nakamura, MD, Division of Hepatobiliary and Pancreatic Medicine, Department of Internal Medicine, Hyogo College of Medicine. Mukogawa-cho 1-1, Nishinomiya 663-8501, Hyogo, Japan; E-mail: nakamura{at}hyo-med.ac.jp.
Background: Hepatoma-derived growth factor (HDGF) is involved in hepatocarcinogenesis, as well as in liver development and regeneration. This study investigated the correlation of HDGF expression with differentiation and prognosis of hepatocellular carcinoma (HCC).
Methods: HDGF expression in 100 patients with HCC (81 men and 19 women) with ages ranging from 34 to 81 years (median, 61 years) receiving surgical treatment was analyzed by immunohistochemistry. HDGF messenger RNA expression was evaluated in 10 cases by reverse transcription-polymerase chain reaction. The immunostaining pattern in HCCs was categorized as a positive HDGF index (showing positive staining in >90% of tumor cells in both nucleus and cytoplasm) or a negative HDGF index (all others).
Results: Twenty-seven cases (27%) showed a positive and 73 (73%) showed a negative HDGF index. HDGF messenger RNA expression was significantly higher in four cases with a positive HDGF index than in six with a negative index. Cases with well-differentiated histological characteristics showed a higher rate of positive HDGF index than those with a poorly differentiated subtype. Univariate and multivariate analysis revealed significantly poorer disease-free and overall survivals in patients with a positive HDGF index compared with patients with a negative index.
Conclusions: These findings suggest the potential utility of HDGF immunohistochemistry in determining the prognosis of HCC.
Key Words: Hepatoma-derived growth factor • Hepatocellular carcinoma • Prognosis • Recurrence
This article has been cited by other articles:
 |
|
 |
|
  H. M. El-Tahir, M. M. Abouzied, R. Gallitzendoerfer, V. Gieselmann, and S. Franken Hepatoma-derived Growth Factor-related Protein-3 Interacts with Microtubules and Promotes Neurite Outgrowth in Mouse Cortical Neurons J. Biol. Chem., April 24, 2009; 284(17): 11637 - 11651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yamamoto, Y. Tomita, Y. Hoshida, E. Morii, T. Yasuda, Y. Doki, K. Aozasa, H. Uyama, H. Nakamura, and M. Monden Expression Level of Hepatoma-Derived Growth Factor Correlates with Tumor Recurrence of Esophageal Carcinoma Ann. Surg. Oncol., July 1, 2007; 14(7): 2141 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Uyama, Y. Tomita, H. Nakamura, S. Nakamori, B. Zhang, Y. Hoshida, H. Enomoto, Y. Okuda, M. Sakon, K. Aozasa, et al. Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Patients with Pancreatic Cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6043 - 6048. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
